Tislelizumab with first chemotherapy for older Hodgkin lymphoma patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests adding tislelizumab (an immune medicine) to standard first-line chemotherapy for people age 60 and older with newly diagnosed classic Hodgkin lymphoma. The goal is to improve how well treatment works while adapting the plan for older adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed classic Hodgkin lymphoma that has not been treated yet
- You are 60 years old or older
- Your medical team feels you can safely receive combination chemotherapy (you may need dose reductions, but not too much)
- CT scans show measurable lymphoma, and you can provide a signed consent form
- Blood tests, liver tests, and kidney function are in acceptable ranges for study treatment
- Heart ultrasound shows your heart pumping is strong enough (left heart ejection fraction 50% or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
This study tests a combination of a newer immunotherapy drug (nivolumab) with standard chemotherapy (AVD) in children, teens, and young adults with newly diagnosed, early-stage Hodgkin lymphoma—a blood cancer affecting lymph nodes. The goal is to see if adding immunotherapy improves outcomes while being tolerable for this age group.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests whether adding the immunotherapy drug nivolumab to the first treatment of advanced Hodgkin lymphoma can improve outcomes. It uses PET scans to guide therapy, potentially reducing the need for stronger chemotherapy.
This Phase 2 study tests whether you can treat early-stage Hodgkin lymphoma with chemotherapy while avoiding radiation. It may help reduce radiation-related side effects if the treatment controls the cancer effectively.
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.